Background
Methods
Clinical sample information
Variables | Cases (n = 685) | Controls (n = 618) |
P* | ||
---|---|---|---|---|---|
N
| % |
N
| % | ||
Age (years) | |||||
≤50 | 376 | 54.89 | 345 | 55.83 | 0.738 |
>50 | 309 | 45.11 | 273 | 44.17 | |
Gender | |||||
Male | 318 | 46.42 | 319 | 51.62 | 0.067 |
Female | 367 | 53.58 | 299 | 48.38 | |
Tumor size (cm) | |||||
≤5 | 478 | 69.78 | |||
>5 | 207 | 30.22 | |||
Differentiation | |||||
Well | 249 | 36.35 | |||
Moderate | 205 | 29.93 | |||
Poor | 231 | 33.72 | |||
Metastasis | |||||
Yes | 412 | 60.15 | |||
No | 273 | 39.85 |
Cell lines and cell culture
Construction of plasmids
Dual-luciferase reporter assay
Cell proliferation assays
Immunohistochemistry (IHC)
Genotype
Statistical analysis
Results
Clinical significance of rs35301225 in CRC
Genotype | Cases (n = 685) | Controls (n = 618) | OR (95%CI)a
|
P valuea
| ||
---|---|---|---|---|---|---|
N
| % |
N
| % | |||
rs35301225 | ||||||
CC | 189 | 27.59 | 328 | 53.07 | 1 |
<0.0001
|
CA | 155 | 22.63 | 184 | 29.77 | 1.15 (1.02–1.11) | |
AA | 341 | 49.78 | 106 | 17.15 | 3.71 (1.12–1.21) | |
A carrier | 496 | 72.41 | 290 | 46.93 | 2.08 (1.19–1.29) |
<0.0001
|
Stratified analysis of correlation between miR-34a polymorphism and CRC
Feather | Genotype | CC vs. AA
P value* | CC vs. A carrier
P value* | |||
---|---|---|---|---|---|---|
CC | CA | AA | A carrier | |||
Age (years) | ||||||
≤50 | 99 | 81 | 196 | 277 | 0.258 | 0.4399 |
>50 | 90 | 74 | 145 | 219 | ||
Gender | ||||||
Male | 80 | 69 | 169 | 238 | 0.11 | 0.1990 |
Female | 109 | 86 | 172 | 258 | ||
Differentiation grade | ||||||
Well | 102 | 75 | 72 | 147 | <0.0001 | <0.0001 |
Moderate | 48 | 69 | 74 | 143 | ||
Poor | 39 | 11 | 195 | 206 | ||
Tumor size (cm) | ||||||
≤5 | 157 | 144 | 177 | 321 | <0.0001 | <0.0001 |
>5 | 32 | 11 | 164 | 175 | ||
Metastasis | ||||||
Yes | 147 | 134 | 131 | 265 | <0.0001 | |
No | 42 | 21 | 210 | 231 | <0.0001 |